These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 13872996)

  • 1. [Cardiovascular manifestatons of acromegaly].
    BRICAIRE H; CHICHE P; ACAR J; BALEDENT P
    Presse Med (1893); 1962 Mar; 70():521-3. PubMed ID: 13872996
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: Health-Related Complications of Acromegaly.
    Bolanowski M; Boguszewski CL; Colao A; Jawiarczyk-Przybyłowska A
    Front Endocrinol (Lausanne); 2020; 11():496. PubMed ID: 32849286
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.
    Ramos-Leví AM; Marazuela M
    Endocrine; 2017 Feb; 55(2):346-359. PubMed ID: 28042644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical consequences of acromegaly: what are the effects of biochemical control?
    Colao A; Auriemma RS; Pivonello R; Galdiero M; Lombardi G
    Rev Endocr Metab Disord; 2008 Mar; 9(1):21-31. PubMed ID: 18163212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The cardiovascular syndrome in acromegalia].
    Annee Endocrinol; 1971; 23():82-4. PubMed ID: 5562235
    [No Abstract]   [Full Text] [Related]  

  • 6. 5 Long-term acromegaly and associated cardiovascular complications: a case-based review.
    Colao A
    Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23 Suppl 1():S31-8. PubMed ID: 20129192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.
    Pivonello R; Auriemma RS; Grasso LF; Pivonello C; Simeoli C; Patalano R; Galdiero M; Colao A
    Pituitary; 2017 Feb; 20(1):46-62. PubMed ID: 28224405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic complications of acromegaly: epidemiology, pathogenesis, and management.
    Colao A; Ferone D; Marzullo P; Lombardi G
    Endocr Rev; 2004 Feb; 25(1):102-52. PubMed ID: 14769829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between symptoms of acromegely and its complications, principally cardiovascular in 86 patients.
    Silinková-Málková E; Kölbel F
    Acta Univ Carol Med (Praha); 1970; 16(5):553-69. PubMed ID: 4254360
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control.
    Berg C; Petersenn S; Lahner H; Herrmann BL; Buchfelder M; Droste M; Stalla GK; Strasburger CJ; Roggenbuck U; Lehmann N; Moebus S; Jöckel KH; Möhlenkamp S; Erbel R; Saller B; Mann K;
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3648-56. PubMed ID: 20463098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acromegaly is always evolutive. Is it a severe disease?].
    Bricaire H; Strauch G
    Presse Med (1893); 1970 Jan; 78(4):159-60. PubMed ID: 5418589
    [No Abstract]   [Full Text] [Related]  

  • 14. The dyslipemic syndrome in acromegaly.
    Ioaniţiu D; Bartoc R; Ispas I; Augustin M; Dimitriu V; Popovici D; Dinulescu E; Marinescu I; Marinescu L; Giurcăneanu M; Mazilu M
    Endocrinologie; 1982; 20(1):25-36. PubMed ID: 7041236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical review 36: Cardiovascular manifestations of endocrine disease.
    Klein I; Ojamaa K
    J Clin Endocrinol Metab; 1992 Aug; 75(2):339-42. PubMed ID: 1639931
    [No Abstract]   [Full Text] [Related]  

  • 16. [Abnormal lipid metabolism in acromegaly].
    Inoue T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():162-6. PubMed ID: 11347050
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular manifestations of endocrine dysfunction.
    Deegan RJ; Furman WR
    J Cardiothorac Vasc Anesth; 2011 Aug; 25(4):705-20. PubMed ID: 21330154
    [No Abstract]   [Full Text] [Related]  

  • 18. [Acromegaly in 2000].
    Gervaise N; Combe H; Lecomte P
    Ann Endocrinol (Paris); 2000 Sep; 61(3):242-52. PubMed ID: 10970950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between biochemical control and cardiovascular risk factors in acromegaly.
    Carmichael JD; Broder MS; Cherepanov D; Chang E; Mamelak A; Said Q; Neary MP; Bonert V
    BMC Endocr Disord; 2017 Mar; 17(1):15. PubMed ID: 28279153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Behavior of the cardiovascular system in acromegaly].
    Pascale C; Caccia M; Cottino A; Gamna G; Molinatti GM
    Boll Soc Ital Cardiol; 1977; 22(6):911-7. PubMed ID: 618234
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.